Amedeo Smart

Free Medical Literature Service

 

Amedeo

Breast Cancer
  Free Subscription

Articles published in
Oncogene
    November 2025
  1. LI M, Xie W, Hu K, Li T, et al
    The novel endogenous micropeptide XLH-36 binds Gemin4 to promote triple-negative breast cancer metastasis.
    Oncogene. 2025 Nov 29. doi: 10.1038/s41388-025-03621.
    >> Share

  2. REINHARDT J, Dankbar B, Geers F, Werbenko E, et al
    Pharmacological inhibition of myostatin effectively ameliorates osteolytic lesions in syngeneic and xenograft breast cancer mouse models.
    Oncogene. 2025 Nov 17. doi: 10.1038/s41388-025-03622.
    >> Share

  3. ZHOU L, Liu M, Liu F, Wang Z, et al
    Circular RNA CLASP1 modulates the GLI1/SNAIL axis and enhances macrophage polarization in breast cancer.
    Oncogene. 2025 Nov 17. doi: 10.1038/s41388-025-03627.
    >> Share

  4. CHEN S, Xiang L, He M, Han Q, et al
    Chaperone-mediated autophagy controlling VEGFR1 degradation contributes cross talk between breast cancer cells and endothelial cells triggering tumorigenesis via the VEGF-VEGFR2 axis.
    Oncogene. 2025 Nov 13. doi: 10.1038/s41388-025-03619.
    >> Share

  5. MEDKOUR Y, Dufour CR, Han L, Hutton P, et al
    Regulation of ribosomal gene expression and senescence by a PML-mTOR-RONIN nuclear complex in triple-negative breast cancer.
    Oncogene. 2025 Nov 8. doi: 10.1038/s41388-025-03623.
    >> Share

    September 2025
  6. CAI Y, Du J, Wang H, Shen L, et al
    KPNA2 silencing sensitizes triple-negative breast cancer to chemotherapy by promoting multipolar division and suppressing DNA damage repair.
    Oncogene. 2025 Sep 18. doi: 10.1038/s41388-025-03503.
    >> Share

  7. CHEN H, Zhou Y, Zhang Y, Fan Y, et al
    TRIM21-mediated ubiquitination of SIX2 attenuates breast cancer stemness via LGSN suppression.
    Oncogene. 2025 Sep 15. doi: 10.1038/s41388-025-03572.
    >> Share

  8. DONG X, Dai H, Yao L, Lin Y, et al
    EMC2 promotes triple negative breast cancer growth by protecting FDFT1 from endoplasmic reticulum associated degradation to impair ferroptosis susceptibility.
    Oncogene. 2025 Sep 10. doi: 10.1038/s41388-025-03545.
    >> Share

  9. UMBRICHT CB, Evron E, Gabrielson E, Ferguson AT, et al
    Correction: Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer.
    Oncogene. 2025 Sep 5. doi: 10.1038/s41388-025-03555.
    >> Share

  10. TIAN L, Jiao X, Wang C, Li D, et al
    PPARgamma acetylation governs mammary adenocarcinoma tumor growth via acetylated residues that determine DNA sequence-specific binding.
    Oncogene. 2025;44:3476-3492.
    >> Share

    August 2025
  11. CHEN X, Ma C, Li Y, Liang Y, et al
    Correction: COL5A1 promotes triple-negative breast cancer progression by activating tumor cell-macrophage crosstalk.
    Oncogene. 2025 Aug 28. doi: 10.1038/s41388-025-03554.
    >> Share

  12. BARNIEH FM, Morton J, Olanrewaju O, El-Khamisy SF, et al
    Decoding the adaptive survival mechanisms of breast cancer dormancy.
    Oncogene. 2025 Aug 27. doi: 10.1038/s41388-025-03529.
    >> Share

  13. MIYAN J, Kumar N, Moinuddin, Malik SA, et al
    Leveraging RAS-mSIN1 interaction to selectively inhibit mTORC2 employing competitive RAS binding peptide: implications in breast cancer metastasis.
    Oncogene. 2025 Aug 23. doi: 10.1038/s41388-025-03516.
    >> Share

  14. HAWES ML, Moody MA, McCauley CR, Huddleston AG, et al
    Oncogenic effects of ECM remodeling in obesity and breast cancer.
    Oncogene. 2025 Aug 22. doi: 10.1038/s41388-025-03521.
    >> Share

  15. GITHAKA JM, Kirschenman R, Patel N, Tripathi N, et al
    Multiple anti-tumor programs are activated by blocking BAD phosphorylation.
    Oncogene. 2025;44:2530-2546.
    >> Share

  16. LIU J, Zhang S, Cao L, Zhang N, et al
    The deubiquitination-PARylation positive feedback loop of the USP10-PARP1 axis promotes DNA damage repair and affects therapeutic efficacy of PARP1 inhibitor.
    Oncogene. 2025;44:2515-2529.
    >> Share

    July 2025
  17. GUO L, Rao Y, Song Y, Hu J, et al
    SIX1 transmits signals for breast cancer progression via the ZEB1/IL6/STAT3 signaling axis.
    Oncogene. 2025 Jul 26. doi: 10.1038/s41388-025-03499.
    >> Share

  18. ZHAO Y, Qiao S, Hou X, Tian H, et al
    Correction: Bioengineered tumor microenvironments with naked mole rats high-molecular-weight hyaluronan induces apoptosis in breast cancer cells.
    Oncogene. 2025 Jul 24. doi: 10.1038/s41388-025-03506.
    >> Share

  19. DURAN CL, Surve CR, Ye X, Chen X, et al
    Targeting CSF-1 signaling between tumor cells and macrophages at TMEM doorways inhibits breast cancer dissemination.
    Oncogene. 2025 Jul 11. doi: 10.1038/s41388-025-03485.
    >> Share

  20. WU W, Wu W, Xie X, Li J, et al
    DNMT1 is required for efficient DSB repair and maintenance of replication fork stability, and its loss reverses resistance to PARP inhibitors in cancer cells.
    Oncogene. 2025;44:2283-2302.
    >> Share

    June 2025
  21. LIU F, Liu W, Tan Y, Shang Y, et al
    PTEN neddylation aggravates CDK4/6 inhibitor resistance in breast cancer.
    Oncogene. 2025 Jun 18. doi: 10.1038/s41388-025-03468.
    >> Share

    May 2025
  22. ANAND V, El-Dana F, Baran N, Borgman J, et al
    GD3 synthase drives resistance to p53-induced apoptosis in breast cancer by modulating mitochondrial function.
    Oncogene. 2025 May 17. doi: 10.1038/s41388-025-03432.
    >> Share

    April 2025
  23. NING W, Yang J, Ni R, Yin Q, et al
    Correction: Hypoxia induced cellular and exosomal RPPH1 promotes breast cancer angiogenesis and metastasis through stabilizing the IGF2BP2/FGFR2 axis.
    Oncogene. 2025 Apr 22. doi: 10.1038/s41388-025-03422.
    >> Share

  24. CHEN W, Jiang M, Zou X, Chen Z, et al
    Fibroblast Activation Protein (FAP)(+) cancer-associated fibroblasts induce macrophage M2-like polarization via the Fibronectin 1-Integrin alpha5beta1 axis in breast cancer.
    Oncogene. 2025 Apr 22. doi: 10.1038/s41388-025-03359.
    >> Share

  25. GAO Y, Li B, Jin Y, Cheng J, et al
    Spatial multi-omics profiling of breast cancer oligo-recurrent lung metastasis.
    Oncogene. 2025 Apr 15. doi: 10.1038/s41388-025-03388.
    >> Share

  26. CHEN S, Tang M, Yu X, Qian W, et al
    A microprotein encoded by LINC00263 promotes breast cancer osteolytic bone metastasis by inducing osteoclastogenesis and inhibiting osteoclast ferroptosis.
    Oncogene. 2025 Apr 12. doi: 10.1038/s41388-025-03400.
    >> Share

  27. PRADEEP C-, Zeisel A, Kostler WJ, Lauriola M, et al
    Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions.
    Oncogene. 2025 Apr 11. doi: 10.1038/s41388-025-03362.
    >> Share

  28. GUO Z, Dong RW, Wu Y, Dong S, et al
    Cyclin-dependent kinase 4 and 6 inhibitors in breast cancer treatment.
    Oncogene. 2025 Apr 8. doi: 10.1038/s41388-025-03378.
    >> Share

  29. MAN KF, Darweesh O, Hong J, Thompson A, et al
    Correction: CREB1-BCL2 drives mitochondrial resilience in RAS GAP-dependent breast cancer chemoresistance.
    Oncogene. 2025 Apr 2. doi: 10.1038/s41388-025-03369.
    >> Share

  30. HUANG J, Luo S, Shen J, Lee M, et al
    Cellular polarity pilots breast cancer progression and immunosuppression.
    Oncogene. 2025;44:783-793.
    >> Share

  31. RANINGA PV, Zeng B, Moi D, Trethowan E, et al
    CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancers.
    Oncogene. 2025;44:893-908.
    >> Share

  32. KIM K, Chadalapaka G, Lee S-, Yamada D, et al
    Editorial Expression of Concern: Identification of oncogenic microRNA-17-92/ZBTB4/specificity protein axis in breast cancer.
    Oncogene. 2025 Apr 1. doi: 10.1038/s41388-025-03363.
    >> Share

  33. JAIN A, Barge A, Parris CN
    Correction: Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms.
    Oncogene. 2025 Apr 1. doi: 10.1038/s41388-025-03364.
    >> Share

  34. MUGISHA S, Baba SA, Labhsetwar S, Dave D, et al
    S100A8/A9 innate immune signaling as a distinct mechanism driving progression of smoking-related breast cancers.
    Oncogene. 2025;44:1051-1062.
    >> Share

    March 2025
  35. WANG H, Wang H, Wang R, Li Y, et al
    Discovery of a molecular glue for EGFR degradation.
    Oncogene. 2025;44:545-556.
    >> Share

  36. ZHANG Z, Li F, Dai X, Deng J, et al
    A novel micropeptide miPEP205 suppresses the growth and metastasis of TNBC.
    Oncogene. 2025;44:513-529.
    >> Share

  37. JI L, Chen J, He L, Zhang F, et al
    Reversal of endocrine resistance via N6AMT1-NEDD4L pathway-mediated p110alpha degradation.
    Oncogene. 2025;44:530-544.
    >> Share

    February 2025
  38. WITKIEWICZ AK, Wang J, Schultz E, O'Connor TN, et al
    Using prognostic signatures and machine learning to identify core features associated with response to CDK4/6 inhibitor-based therapy in metastatic breast cancer.
    Oncogene. 2025 Feb 26. doi: 10.1038/s41388-025-03308.
    >> Share

  39. KONG Y, Lan T, Wang L, Gong C, et al
    Correction: BRD4-specific PROTAC inhibits basal-like breast cancer partially through downregulating KLF5 expression.
    Oncogene. 2025 Feb 3. doi: 10.1038/s41388-024-03250.
    >> Share

  40. GAO ZX, Li CL, Zhang H, Zhang GH, et al
    LINC00882, transcriptionally activated by CEBP-beta and post-transcriptionally stabilized by METTL14-mediated m(6)A modification, exerts tumorigenesis by promoting PABPC1-mediated stabilization of ELK3 mRNA.
    Oncogene. 2025;44:363-377.
    >> Share

    January 2025
  41. MAN KF, Darweesh O, Hong J, Thompson A, et al
    CREB1-BCL2 drives mitochondrial resilience in RAS GAP-dependent breast cancer chemoresistance.
    Oncogene. 2025 Jan 31. doi: 10.1038/s41388-025-03284.
    >> Share

    December 2024
  42. GILLESPIE MS, Chiang K, Regan-Mochrie GL, Choi SY, et al
    PRMT5-regulated splicing of DNA repair genes drives chemoresistance in breast cancer stem cells.
    Oncogene. 2024 Dec 18. doi: 10.1038/s41388-024-03264.
    >> Share

  43. TANG T, Yang T, Xue H, Liu X, et al
    Breast cancer stem cell-derived exosomal lnc-PDGFD induces fibroblast-niche formation and promotes lung metastasis.
    Oncogene. 2024 Dec 4. doi: 10.1038/s41388-024-03237.
    >> Share

    November 2024
  44. JAIN A, Barge A, Parris CN
    Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms.
    Oncogene. 2024 Nov 21. doi: 10.1038/s41388-024-03227.
    >> Share

  45. ESCOTO A, Hecksel R, Parkinson C, Crane S, et al
    Nuclear EGFR in breast cancer suppresses NK cell recruitment and cytotoxicity.
    Oncogene. 2024 Nov 9. doi: 10.1038/s41388-024-03211.
    >> Share

  46. NING W, Yang J, Ni R, Yin Q, et al
    Hypoxia induced cellular and exosomal RPPH1 promotes breast cancer angiogenesis and metastasis through stabilizing the IGF2BP2/FGFR2 axis.
    Oncogene. 2024 Nov 4. doi: 10.1038/s41388-024-03213.
    >> Share

    September 2024
  47. XIONG J, Zhou Z, Jiang Y, Li Q, et al
    Hypoxic stabilization of RIPOR3 mRNA via METTL3-mediated m(6)A methylation drives breast cancer progression and metastasis.
    Oncogene. 2024 Sep 28. doi: 10.1038/s41388-024-03180.
    >> Share

  48. ZHANG C, Lu YJ, Wang M, Chen B, et al
    Characterisation of APOBEC3B-Mediated RNA editing in breast cancer cells reveals regulatory roles of NEAT1 and MALAT1 lncRNAs.
    Oncogene. 2024 Sep 25. doi: 10.1038/s41388-024-03171.
    >> Share

  49. YOUSAFZAI NA, El Khalki L, Wang W, Szpendyk J, et al
    Kindlin-2 regulates the oncogenic activities of integrins and TGF-beta in triple-negative breast cancer progression and metastasis.
    Oncogene. 2024 Sep 19. doi: 10.1038/s41388-024-03166.
    >> Share

  50. ZHAO G, Zhang X, Meng L, Dong K, et al
    Single-cell RNA-sequencing reveals a unique landscape of the tumor microenvironment in obesity-associated breast cancer.
    Oncogene. 2024 Sep 16. doi: 10.1038/s41388-024-03161.
    >> Share

  51. FERNANDO W, Cruickshank BM, Arun RP, MacLean MR, et al
    ALDH1A3 is the switch that determines the balance of ALDH(+) and CD24(-)CD44(+) cancer stem cells, EMT-MET, and glucose metabolism in breast cancer.
    Oncogene. 2024 Sep 9. doi: 10.1038/s41388-024-03156.
    >> Share

  52. GRASSET EM, Deshpande A, Lee JW, Cho Y, et al
    Mapping the breast tumor microenvironment: proximity analysis reveals spatial relationships between macrophage subtypes and metastasis-initiating cancer cells.
    Oncogene. 2024;43:2927-2937.
    >> Share

    August 2024
  53. KONG Y, Lan T, Wang L, Gong C, et al
    BRD4-specific PROTAC inhibits basal-like breast cancer partially through downregulating KLF5 expression.
    Oncogene. 2024 Aug 20. doi: 10.1038/s41388-024-03121.
    >> Share

  54. YU S, Wu R, Si Y, Fan Z, et al
    Alternative splicing of ALDOA confers tamoxifen resistance in breast cancer.
    Oncogene. 2024 Aug 20. doi: 10.1038/s41388-024-03134.
    >> Share

  55. CORBIN J, Yu X, Jin J, Cai L, et al
    EZH2 PROTACs target EZH2- and FOXM1-associated oncogenic nodes, suppressing breast cancer cell growth.
    Oncogene. 2024 Aug 7. doi: 10.1038/s41388-024-03119.
    >> Share

    July 2024
  56. LESLIE TK, Tripp A, James AD, Fraser SP, et al
    A novel Na(v)1.5-dependent feedback mechanism driving glycolytic acidification in breast cancer metastasis.
    Oncogene. 2024 Jul 25. doi: 10.1038/s41388-024-03098.
    >> Share

  57. HAN X, Ren C, Lu C, Jiang A, et al
    Phosphorylation of USP27X by PIM2 promotes glycolysis and breast cancer progression via deubiquitylation of MYC.
    Oncogene. 2024 Jul 5. doi: 10.1038/s41388-024-03097.
    >> Share

    June 2024
  58. CASCIO S, Bartella V, Auriemma A, Johannes GJ, et al
    Retraction Note: Mechanism of leptin expression in breast cancer cells: role of hypoxia-inducible factor-1alpha.
    Oncogene. 2024 Jun 20. doi: 10.1038/s41388-024-03087.
    >> Share

  59. SIRKISOON SR, Carpenter RL, Rimkus T, Anderson A, et al
    Correction: Interaction between STAT3 and GLI1/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer.
    Oncogene. 2024 Jun 12. doi: 10.1038/s41388-024-03084.
    >> Share

  60. LEE SG, Woo SM, Seo SU, Lee HS, et al
    Non-canonical deubiquitination of OTUB1 induces IFNgamma-mediated cell cycle arrest via regulation of p27 stability.
    Oncogene. 2024;43:1852-1860.
    >> Share

    May 2024
  61. DORE S, Ali M, Sorin M, McDowell SAC, et al
    Exploring the prognostic significance of arm-level copy number alterations in triple-negative breast cancer.
    Oncogene. 2024 May 14. doi: 10.1038/s41388-024-03051.
    >> Share

  62. DAS C, Bhattacharya A, Adhikari S, Mondal A, et al
    A prismatic view of the epigenetic-metabolic regulatory axis in breast cancer therapy resistance.
    Oncogene. 2024 May 8. doi: 10.1038/s41388-024-03054.
    >> Share

  63. MA J, Chen Y, Li T, Cao Y, et al
    Suppression of lysosome metabolism-meditated GARP/TGF-beta1 complexes specifically depletes regulatory T cells to inhibit breast cancer metastasis.
    Oncogene. 2024 May 2. doi: 10.1038/s41388-024-03043.
    >> Share

  64. LAISNE M, Rodgers B, Benlamara S, Wicinski J, et al
    A novel bioinformatic approach reveals cooperation between Cancer/Testis genes in basal-like breast tumors.
    Oncogene. 2024;43:1369-1385.
    >> Share

    April 2024
  65. DOHENY D, Sirkisoon S, Carpenter RL, Aguayo NR, et al
    Correction: Combined inhibition of JAK2-STAT3 and SMO-GLI1/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis.
    Oncogene. 2024 Apr 27. doi: 10.1038/s41388-024-03046.
    >> Share

  66. ZHOU Z, Zheng X, Zhao J, Yuan A, et al
    ULK1-dependent phosphorylation of PKM2 antagonizes O-GlcNAcylation and regulates the Warburg effect in breast cancer.
    Oncogene. 2024 Apr 17. doi: 10.1038/s41388-024-03035.
    >> Share

  67. CHEN X, Ma C, Li Y, Liang Y, et al
    COL5A1 promotes triple-negative breast cancer progression by activating tumor cell-macrophage crosstalk.
    Oncogene. 2024 Apr 12. doi: 10.1038/s41388-024-03030.
    >> Share

  68. BOTTONI L, Minetti A, Realini G, Pio E, et al
    NRF2 activation by cysteine as a survival mechanism for triple-negative breast cancer cells.
    Oncogene. 2024 Apr 10. doi: 10.1038/s41388-024-03025.
    >> Share

  69. RUSSO GC, Crawford AJ, Clark D, Cui J, et al
    Correction: E-cadherin interacts with EGFR resulting in hyper-activation of ERK in multiple models of breast cancer.
    Oncogene. 2024 Apr 5. doi: 10.1038/s41388-024-03023.
    >> Share

    March 2024
  70. RUSSO GC, Crawford AJ, Clark D, Cui J, et al
    E-cadherin interacts with EGFR resulting in hyper-activation of ERK in multiple models of breast cancer.
    Oncogene. 2024 Mar 20. doi: 10.1038/s41388-024-03007.
    >> Share

  71. MCCLELLAN B, Wilson CN, Brenner AJ, Jolly CA, et al
    Flotillin-1 palmitoylation is essential for its stability and subsequent tumor promoting capabilities.
    Oncogene. 2024;43:1063-1074.
    >> Share

    February 2024
  72. PRADEEP C-, Zeisel A, Kostler WJ, Lauriola M, et al
    Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions.
    Oncogene. 2024 Feb 28. doi: 10.1038/s41388-024-02990.
    >> Share

  73. YANG L, Wang M, Wang Y, Zhu Y, et al
    LINC00460-FUS-MYC feedback loop drives breast cancer metastasis and doxorubicin resistance.
    Oncogene. 2024 Feb 28. doi: 10.1038/s41388-024-02972.
    >> Share

  74. ZHENG XQ, Guo JP, Yang H, Kanai M, et al
    Retraction Note: Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERalpha in breast cancer.
    Oncogene. 2024 Feb 23. doi: 10.1038/s41388-024-02983.
    >> Share

  75. BARRA J, Crosbourne I, Roberge CL, Bossardi-Ramos R, et al
    DMT1-dependent endosome-mitochondria interactions regulate mitochondrial iron translocation and metastatic outgrowth.
    Oncogene. 2024;43:650-667.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016